SCI Pharmtech, Inc. (4119.TW)
TWD 89.9
(-0.66%)
TWD 89.9
(-0.66%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 529.53 Million TWD | 3.14% |
| 2022 | 513.43 Million TWD | 74.53% |
| 2021 | 294.18 Million TWD | -22.76% |
| 2020 | 380.87 Million TWD | -27.74% |
| 2019 | 527.08 Million TWD | 4.77% |
| 2018 | 503.07 Million TWD | 4.19% |
| 2017 | 482.82 Million TWD | -3.12% |
| 2016 | 498.35 Million TWD | -10.04% |
| 2015 | 553.99 Million TWD | 8.62% |
| 2014 | 510.02 Million TWD | 25.36% |
| 2013 | 406.84 Million TWD | 38.75% |
| 2012 | 293.21 Million TWD | -5.66% |
| 2011 | 310.8 Million TWD | 19.44% |
| 2010 | 260.21 Million TWD | 24.93% |
| 2009 | 208.28 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 601.18 Million TWD | 13.53% |
| 2024 Q2 | 635.27 Million TWD | 5.67% |
| 2023 Q4 | 529.53 Million TWD | 2.01% |
| 2023 Q2 | 487.44 Million TWD | -6.45% |
| 2023 Q3 | 519.07 Million TWD | 6.49% |
| 2023 FY | 529.53 Million TWD | 3.14% |
| 2023 Q1 | 521.05 Million TWD | 1.49% |
| 2022 Q4 | 513.43 Million TWD | 20.01% |
| 2022 Q3 | 427.8 Million TWD | -7.52% |
| 2022 FY | 513.43 Million TWD | 74.53% |
| 2022 Q2 | 462.58 Million TWD | 32.88% |
| 2022 Q1 | 348.13 Million TWD | 18.34% |
| 2021 Q2 | 249.77 Million TWD | 0.9% |
| 2021 Q4 | 294.18 Million TWD | 11.72% |
| 2021 FY | 294.18 Million TWD | -22.76% |
| 2021 Q1 | 247.54 Million TWD | -35.01% |
| 2021 Q3 | 263.31 Million TWD | 5.42% |
| 2020 FY | 380.87 Million TWD | -27.74% |
| 2020 Q3 | 475.96 Million TWD | -9.13% |
| 2020 Q4 | 380.87 Million TWD | -19.98% |
| 2020 Q1 | 423.54 Million TWD | -19.64% |
| 2020 Q2 | 523.8 Million TWD | 23.67% |
| 2019 Q1 | 517.59 Million TWD | 2.89% |
| 2019 FY | 527.08 Million TWD | 4.77% |
| 2019 Q4 | 527.08 Million TWD | 8.74% |
| 2019 Q3 | 484.73 Million TWD | -6.67% |
| 2019 Q2 | 519.38 Million TWD | 0.35% |
| 2018 Q2 | 471.73 Million TWD | 4.95% |
| 2018 Q4 | 503.07 Million TWD | 9.08% |
| 2018 FY | 503.07 Million TWD | 4.19% |
| 2018 Q1 | 449.46 Million TWD | -6.91% |
| 2018 Q3 | 461.17 Million TWD | -2.24% |
| 2017 Q3 | 492.66 Million TWD | -5.06% |
| 2017 FY | 482.82 Million TWD | -3.12% |
| 2017 Q4 | 482.82 Million TWD | -2.0% |
| 2017 Q2 | 518.9 Million TWD | 7.49% |
| 2017 Q1 | 482.72 Million TWD | -3.14% |
| 2016 Q3 | 428.02 Million TWD | -12.04% |
| 2016 Q4 | 498.35 Million TWD | 16.43% |
| 2016 FY | 498.35 Million TWD | -10.04% |
| 2016 Q1 | 522.4 Million TWD | -5.7% |
| 2016 Q2 | 486.62 Million TWD | -6.85% |
| 2015 Q4 | 553.99 Million TWD | 17.3% |
| 2015 Q3 | 472.27 Million TWD | -1.35% |
| 2015 Q2 | 478.76 Million TWD | -4.43% |
| 2015 Q1 | 500.93 Million TWD | -1.78% |
| 2015 FY | 553.99 Million TWD | 8.62% |
| 2014 FY | 510.02 Million TWD | 25.36% |
| 2014 Q4 | 510.02 Million TWD | 9.79% |
| 2014 Q3 | 464.52 Million TWD | 0.68% |
| 2014 Q2 | 461.4 Million TWD | 13.52% |
| 2014 Q1 | 406.46 Million TWD | -0.09% |
| 2013 FY | 406.84 Million TWD | 38.75% |
| 2013 Q1 | 322.17 Million TWD | 9.88% |
| 2013 Q2 | 342.66 Million TWD | 6.36% |
| 2013 Q3 | 354.93 Million TWD | 3.58% |
| 2013 Q4 | 406.84 Million TWD | 14.62% |
| 2012 Q4 | 293.21 Million TWD | 19.98% |
| 2012 Q2 | 254.86 Million TWD | 4.07% |
| 2012 FY | 293.21 Million TWD | -5.66% |
| 2012 Q1 | 244.89 Million TWD | -21.21% |
| 2012 Q3 | 244.38 Million TWD | -4.11% |
| 2011 Q1 | 278.96 Million TWD | 7.21% |
| 2011 Q2 | 276.26 Million TWD | -0.97% |
| 2011 Q3 | 277.73 Million TWD | 0.53% |
| 2011 Q4 | 310.8 Million TWD | 11.91% |
| 2011 FY | 310.8 Million TWD | 19.44% |
| 2010 FY | 260.21 Million TWD | 24.93% |
| 2010 Q4 | 260.21 Million TWD | 0.0% |
| 2009 FY | 208.28 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Grape King Bio Ltd | 737.18 Million TWD | 28.168% |
| Standard Chem & Pharm CO., LTD. | 1.61 Billion TWD | 67.211% |
| Maywufa Company Ltd. | 257.91 Million TWD | -105.316% |
| ScinoPharm Taiwan, Ltd. | 1.51 Billion TWD | 64.967% |
| Lotus Pharmaceutical Co., Ltd. | 3.77 Billion TWD | 85.974% |
| LIWANLI Innovation Co., Ltd. | 60.81 Million TWD | -770.67% |
| YungShin Global Holding Corporation | 2.77 Billion TWD | 80.904% |
| PhytoHealth Corporation | 163.09 Million TWD | -224.688% |
| Formosa Laboratories, Inc. | 1.59 Billion TWD | 66.852% |
| PharmaEssentia Corporation | 1.45 Billion TWD | 63.697% |
| Bora Pharmaceuticals Co., LTD. | 2.15 Billion TWD | 75.441% |